

PATENT APPLICATION / LOV

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Huang et al.

Serial No.:

10/615,809

Group Art Unit No.: 1626

Filed:

July 8, 2003

Examiner: Janet L. Coppins

For:

SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE

Docket No.: A-817

## INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

٥

As a means of complying with the duty of disclosure under 37 CFR 1.97 and 1.98, applicant(s) submit(s) a "List of References Cited by Applicant" on a modified PTO-1449 form and provide(s) a copy of each of the listed references for consideration by the Examiner.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicant(s) request(s) consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Joseph W. Bulock

Attorney/Agent for Applicant(s)

Joseph W Balack

Registration No.: 37,103 Phone: (805) 447-7966 Date: July 27, 2005

## **EXPRESS MAIL CERTIFICATE**

"Express Mail" mail labeling number:	EL732826882US	Date of Deposit:		July 27, 2005	
I hereby certify that this paper or fee is bein	g deposited with the United States Postal Sen	vice "Express Mail Post Office to di	/ Idressee* s	ervice under 37 C.F.R. 1.10	on the date
Lisa H		Itulia, VA 22313-1450			
Printed	Name		S	Signature	

## **PATENT APPLICATION**

Please send all future correspondence to:

US Patent Operations/JWB Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

_		
Modified Form PTO-1449	Atty. Docket No.	Serial No.
OF	A-817	10/615.809
LIST OF REFERENCES CITED BY APPLICANT	Applicant	
<u> </u>	Huang et al.	
1 2005 (Use several sheets if necessary)	Filing Date	Group
	July 8, 2003	l 1626

U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A9	6,635,657 B1	21 Oct 2003	Beight et al.			
	A10	6,605,626 B2	12 Aug 2003	Beight et al.			
	A11	6,417,200 B1	9 July 2002	Beight et al.			
	A12	6,372,759 B1	16 Apr 2002	Beight et al.			
	A13	6,313,122 B1	6 Nov 2001	Beight et al.			
	A14	6,313,151 B1	6 Nov 2001	Beight et al.			
	A15	6,610,704 B1	26 Aug 2003	Beight et al.			
	A16	2003/0069250 A1	10 Apr 2003	Zhu et al.			
	A17	2004/0254185 A1	16 Dec 2004	Ernst et al.			
	A18	6,051,713	18 Apr 2000	Teng et al.			
	A19	4,816,485	28 Mar 1989	Satzinger et al.			
	A20	4,857,662	15 Aug 1989	Satzinger et al.			
	A21	6,156,766	5 Dec 2000	Arita et al.			
	A22	4,321,371	23 Mar 1982	Parg et al.			
	A23	2004/0102441 A1	27 May 2004	Krueger et al.			
	A24	5,559,135	24 Sep 1996	Ashton et al.			
	A25	6,593,352 B2	15 July 2003	Weichert et al.			
· · · · · ·	A26	6,660,755 B2	9 Dec 2003	Song et al.			
	A27	6,448,290 B1	10 Sep 2002	Ohuchida et al.			
	A28	3,822,277	2 July 1974	Claude Dufour		1	
	A29	5,770,613	23 Jun 1998	Gaeta et al.			
	A30	5,571,912	5 Nov 1996	Grozinger et al.			
	A31	3,406,168	15 Oct 1968	Gunther Schmidt			
	A32	6,008,234	28 Dec 1999	Kochanny et al.			
	A33	2004/0063775 A1	1 Apr 2004	Momose et al.			

EXAMINER:	Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	_					Sheet	2 Of	2
Modified For	rm PTO-144	49		Atty. Docket No.	Seria	al No.	10/015	000
1.10	ST OF R	EFERENCES CITED BY	APPLICANT	A-817 Applicant			10/615.	809
L.	51 OI III			Huang et al.				
		(Use several sheets if necessar	у)	Filing Date July 8, 2003	Grou		626	
			II C DATE				020	
EXAMINER'S	T	DOCUMENT NUMBER	DATE	NT DOCUMENTS NAME	CLASS	SUB-	FILING	DATE IF
INITIALS						CLASS	APPRO	PRIATE
	A34	2003/0195192 A1	16 Oct 2003	Haviv et al.	<u> </u>			
	A35	2003/0195195 A1	16 Oct 2003	Haviv et al.				
	A36	2005/0032816 A1	10 Feb 2005	Ernst et al.				
	A37	6,794,397 B2	21 Sep 2004	Cai et al.				
	A38_	2005/0054654 A1	10 Mar 2005	Huth et al.				
	A39	6,271,237 B1	7 Aug 2001	Galemmo, Jr. et al.				
			FOREIGN PA	TENT DOCUMENTS				
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	COUNTRY CLASS		SUB- CLASS	TRANSLATION YES NO	
	B36	WO 03/068235 A1	21 Aug 2003	PCT				
	B37	WO 03/068232 A1	21 Aug 2003	PCT				
	B38	EP 0 429 987 A2	5 Jun 1991	Europe				
	B39	EP 0 393 529 B1	30 Jun 1993	Europe				
	B40	EP 0 410 148 A1	30 Jan 1991	Europe				
	B41	EP 0 393 529 A1	24 Oct 1990	Europe				
EXAMINER'S INITIALS	C	THER DOCUMENTS	(Including Pu	ublisher, Author, Title, Date, I	Pertiner	nt Pages	s, Etc.)	
	C9	Proudfoot et al., "Novel Non-nucleoside Inhibitors or HIV-1 Reverse Transcriptase. 3. Dipyrido[2,3-b:2',3'-						
		e]diazepinones", J. Med. Chem., 38:1406-1410 (1995).						
	C10	Smrckova-Voltrova et al., "Structure and Properties of Quaternized 2- and 4-aminonicotinamides", Collect. Czech. Chem. Commun., 50:1009-1015 (1995).						
	C11	Samvelyan et al., "Discussion of Some New Amino Acid Derivatives of Nicotinic Acid and Their Antisoporific Properties", Farmakologiia I Toksikologiia, 49(3):35-37 (1986).						
	C12	Hargrave et al., "Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones", J. Med. Chem., 34:2231-2241 (1991).						

EXAMINER:	Date Considered:

C13

Adams et al., "Discovery and Development of a Non-nucleoside Reverse Transcriptase Inhibitor", Royal

Society of Chemistry, Recent Advances in the Chemistry of Anti-infective Agents, 19:282-296 (1993).

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.